This report provides a comprehensive analysis of the global nucleic acid and oligonucleotide therapeutics market, projecting steady growth through 2032. It examines various product types, including antisense oligonucleotides, siRNA, and mRNA, across applications such as neuromuscular diseases and COVID-19. The study offers detailed regional insights spanning the Americas, APAC, and Europe, while evaluating key industry players like Ionis Pharmaceuticals and Alnylam. Furthermore, it explores critical market dynamics, competitive strategies, and emerging opportunities within this evolving pharmaceutical landscape.

Market Overview

The global Nucleic Acid and Oligonucleotide Therapeutics market size is predicted to grow from US$ 13090 million in 2025 to US$ 16980 million in 2032; it is expected to grow at a CAGR of 3.9% from 2026 to 2032.

Product Definition

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.

Regional Market Outlook

• United States: The market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to experience growth from 2025 through 2032.
• China: The market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to experience growth from 2025 through 2032.
• Europe: The market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to experience growth from 2025 through 2032.

Market Segmentation

By Type

• Antisense Oligonucleotides (ASO)
• siRNA
• mRNA

By Application

• Neuromuscular Diseases
• hATTR
• COVID-19
• Other

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on inputs gathered from primary experts and analysis of their coverage, product portfolio, and market penetration:

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Biogen
• Nippon Shinyaku
• Sobi
• Novartis
• BioNTech
• Pfizer
• Moderna Therapeutics
• Jazz Pharmaceuticals
• CureVac
• Regulus Therapeutics
• ProQR
• Secarna
• MiNA Therapeutics
• Sylentis
• Arrowhead
• Silence Therapeutics
• Dicerna

Market Concentration

In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

About the Report

LPI (LP Information)' newest research report, the “Nucleic Acid and Oligonucleotide Therapeutics Industry Forecast” looks at past sales and reviews total world Nucleic Acid and Oligonucleotide Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Nucleic Acid and Oligonucleotide Therapeutics sales for 2026 through 2032. With Nucleic Acid and Oligonucleotide Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid and Oligonucleotide Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Nucleic Acid and Oligonucleotide Therapeutics landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

This report also analyses the strategies of leading global companies with a focus on:

• Nucleic Acid and Oligonucleotide Therapeutics portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

To better understand these firms’ unique position in an accelerating global Nucleic Acid and Oligonucleotide Therapeutics market, the report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid and Oligonucleotide Therapeutics market. The report presents a comprehensive overview, market shares, and growth opportunities of the market by product type, application, key players, and key regions and countries.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021-2032)

    • 2.1.2 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Nucleic Acid and Oligonucleotide Therapeutics by Country/Region (2021, 2025 & 2032)

  • 2.2 Nucleic Acid and Oligonucleotide Therapeutics Segment by Type

    • 2.2.1 Antisense Oligonucleotides (ASO)

    • 2.2.2 siRNA

    • 2.2.3 mRNA

    • 2.2.4 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type

      • 2.2.4.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2021-2026)

  • 2.3 Nucleic Acid and Oligonucleotide Therapeutics Segment by Application

    • 2.3.1 Neuromuscular Diseases

    • 2.3.2 hATTR

    • 2.3.3 COVID-19

    • 2.3.4 Other

    • 2.3.5 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application

      • 2.3.5.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.5.2 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2021-2026)

• 3 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Player

  • 3.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Player

    • 3.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Player (2021-2026)

    • 3.1.2 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player (2021-2026)

  • 3.2 Global Nucleic Acid and Oligonucleotide Therapeutics Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Nucleic Acid and Oligonucleotide Therapeutics by Region

  • 4.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2021-2026)

  • 4.2 Global Nucleic Acid and Oligonucleotide Therapeutics Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2021-2026)

  • 4.4 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2021-2026)

  • 4.5 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021-2026)

  • 5.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2021-2026)

  • 5.3 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2021-2026)

  • 6.2 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2021-2026)

  • 6.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021-2026)

  • 7.2 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2021-2026)

  • 7.3 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics by Region (2021-2026)

  • 8.2 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Nucleic Acid and Oligonucleotide Therapeutics Market Forecast

  • 10.1 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2027-2032)

    • 10.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2027-2032)

    • 10.1.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.1.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.1.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.1.5 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Forecast

  • 10.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Forecast by Country (2027-2032)

    • 10.2.1 United States Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.2.2 Canada Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.2.3 Mexico Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.2.4 Brazil Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

  • 10.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2027-2032)

    • 10.3.1 China Nucleic Acid and Oligonucleotide Therapeutics Market Forecast

    • 10.3.2 Japan Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.3.3 Korea Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.3.4 Southeast Asia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.3.5 India Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.3.6 Australia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

  • 10.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.4.2 France Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.4.3 UK Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.4.4 Italy Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.4.5 Russia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

  • 10.5 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.5.2 South Africa Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.5.3 Israel Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

    • 10.5.4 Turkey Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

  • 10.6 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Type (2027-2032)

  • 10.7 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Nucleic Acid and Oligonucleotide Therapeutics Forecast

• 11 Key Players Analysis

  • 11.1 Sarepta Therapeutics

    • 11.1.1 Sarepta Therapeutics Company Information

    • 11.1.2 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Sarepta Therapeutics Main Business Overview

    • 11.1.5 Sarepta Therapeutics Latest Developments

  • 11.2 Ionis Pharmaceuticals

    • 11.2.1 Ionis Pharmaceuticals Company Information

    • 11.2.2 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Ionis Pharmaceuticals Main Business Overview

    • 11.2.5 Ionis Pharmaceuticals Latest Developments

  • 11.3 Alnylam

    • 11.3.1 Alnylam Company Information

    • 11.3.2 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.3.3 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Alnylam Main Business Overview

    • 11.3.5 Alnylam Latest Developments

  • 11.4 Biogen

    • 11.4.1 Biogen Company Information

    • 11.4.2 Biogen Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.4.3 Biogen Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Biogen Main Business Overview

    • 11.4.5 Biogen Latest Developments

  • 11.5 Nippon Shinyaku

    • 11.5.1 Nippon Shinyaku Company Information

    • 11.5.2 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Nippon Shinyaku Main Business Overview

    • 11.5.5 Nippon Shinyaku Latest Developments

  • 11.6 Sobi

    • 11.6.1 Sobi Company Information

    • 11.6.2 Sobi Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.6.3 Sobi Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Sobi Main Business Overview

    • 11.6.5 Sobi Latest Developments

  • 11.7 Novartis

    • 11.7.1 Novartis Company Information

    • 11.7.2 Novartis Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.7.3 Novartis Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Novartis Main Business Overview

    • 11.7.5 Novartis Latest Developments

  • 11.8 BioNTech

    • 11.8.1 BioNTech Company Information

    • 11.8.2 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.8.3 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 BioNTech Main Business Overview

    • 11.8.5 BioNTech Latest Developments

  • 11.9 Pfizer

    • 11.9.1 Pfizer Company Information

    • 11.9.2 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.9.3 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Pfizer Main Business Overview

    • 11.9.5 Pfizer Latest Developments

  • 11.10 Moderna Therapeutics

    • 11.10.1 Moderna Therapeutics Company Information

    • 11.10.2 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Moderna Therapeutics Main Business Overview

    • 11.10.5 Moderna Therapeutics Latest Developments

  • 11.11 Jazz Pharmaceuticals

    • 11.11.1 Jazz Pharmaceuticals Company Information

    • 11.11.2 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Jazz Pharmaceuticals Main Business Overview

    • 11.11.5 Jazz Pharmaceuticals Latest Developments

  • 11.12 CureVac

    • 11.12.1 CureVac Company Information

    • 11.12.2 CureVac Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.12.3 CureVac Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 CureVac Main Business Overview

    • 11.12.5 CureVac Latest Developments

  • 11.13 Regulus Therapeutics

    • 11.13.1 Regulus Therapeutics Company Information

    • 11.13.2 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Regulus Therapeutics Main Business Overview

    • 11.13.5 Regulus Therapeutics Latest Developments

  • 11.14 ProQR

    • 11.14.1 ProQR Company Information

    • 11.14.2 ProQR Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.14.3 ProQR Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 ProQR Main Business Overview

    • 11.14.5 ProQR Latest Developments

  • 11.15 Secarna

    • 11.15.1 Secarna Company Information

    • 11.15.2 Secarna Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.15.3 Secarna Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Secarna Main Business Overview

    • 11.15.5 Secarna Latest Developments

  • 11.16 MiNA Therapeutics

    • 11.16.1 MiNA Therapeutics Company Information

    • 11.16.2 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 MiNA Therapeutics Main Business Overview

    • 11.16.5 MiNA Therapeutics Latest Developments

  • 11.17 Sylentis

    • 11.17.1 Sylentis Company Information

    • 11.17.2 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.17.3 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Sylentis Main Business Overview

    • 11.17.5 Sylentis Latest Developments

  • 11.18 Arrowhead

    • 11.18.1 Arrowhead Company Information

    • 11.18.2 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Arrowhead Main Business Overview

    • 11.18.5 Arrowhead Latest Developments

  • 11.19 Silence Therapeutics

    • 11.19.1 Silence Therapeutics Company Information

    • 11.19.2 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 Silence Therapeutics Main Business Overview

    • 11.19.5 Silence Therapeutics Latest Developments

  • 11.20 Dicerna

    • 11.20.1 Dicerna Company Information

    • 11.20.2 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product Offered

    • 11.20.3 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 Dicerna Main Business Overview

    • 11.20.5 Dicerna Latest Developments

• 12 Research Findings and Conclusion